How many insider trades does FilingIQ track for PLRX?

FilingIQ tracks 191 Form 4 insider transactions for PLRX (PLIANT THERAPEUTICS, INC.), covering filings from Jun 9, 2020 onwards. 0 of those are dated within the last 90 days.

Are PLRX insiders net buyers or net sellers?

Across the full Form 4 history for PLRX, 0 transactions (0%) were open-market purchases and 103 (54%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does PLRX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.

What sector is PLRX in?

PLIANT THERAPEUTICS, INC. (PLRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $72.44M.

PLRX insider trading

NasdaqGS Healthcare

PLIANT THERAPEUTICS, INC.: insider trade history from SEC Form 4 filings.

Total Form 4 trades

191

Last 90 days

Buys / sells

0% / 54%

Market cap

$72.44M

About PLIANT THERAPEUTICS, INC.

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Company website: pliantrx.com

PLRX insider activity at a glance

FilingIQ tracks 191 insider transactions for PLRX in filings since Jun 9, 2020. The most recent transaction is dated Jan 20, 2026.

Across the full history, 0 open-market purchases and 103 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

View live PLRX trades on FilingIQ Raw filings on SEC EDGAR

Latest PLRX Form 4 filings

Raben David Chief Medical Officer

Kuo Minnie Chief Operating Officer

AD Apr 17, 2026

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 820

UNITED THERAPEUTICS Corp

THERMO FISHER SCIENTIFIC INC.

NTRA 129

Natera, Inc.

ATTO 123

Attovia Therapeutics, Inc.

CORT 110

CORCEPT THERAPEUTICS INC

TEM 104

Tempus AI, Inc.

Frequently asked

How many insider trades does FilingIQ track for PLRX?: FilingIQ tracks 191 Form 4 insider transactions for PLRX (PLIANT THERAPEUTICS, INC.), covering filings from Jun 9, 2020 onwards. 0 of those are dated within the last 90 days.
Are PLRX insiders net buyers or net sellers?: Across the full Form 4 history for PLRX, 0 transactions (0%) were open-market purchases and 103 (54%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does PLRX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
What sector is PLRX in?: PLIANT THERAPEUTICS, INC. (PLRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $72.44M.

Methodology & sources

Every PLRX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.